Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Complete title: AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Research Study Number AALL1331
 
Principal Investigator Rebecca Gardner, MD
 
Phase III

Research Study Description

This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number AALL1331
 
Contact Lindsey Jackson
 
Telephone 206/884-7313
 
E-mail
 

Keywords: Leukemia, Acute Lymphoblastic (ALL); Lymphoma, Burkitt; Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Lymphoma, Non-Hodgkin (NHL); Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Epstein-Barr Virus Infections; Herpesviridae Infections; Immune System Diseases; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials